LONDON (Alliance News) - Allergy Therapeutics PLC said Monday it saw positive results from its grass pollen allergy treatment phase II dose ranging study as it prepares to commence in phase III clinical trial.
The biotechnology company said that it explored the safety and response of different cumulative doses of its Grass Modified Allergen Tyrosine Absorbed MPL for grass-pollen induced seasonal allergic rhinitis.
The trials took place in Germany, Poland and Austria and involved 447 patients.
Allergy Therapeutics said that during the study it evaluated the change in allergic symptoms and identified an optimal dose recommended for Phase III development, which it plans to begin in 2019.
"We are thrilled with these extremely positive results demonstrating dose dependent efficacy of the product including the current marketed dose," said Chief Executive Manuel Llobet. "This study represents a major milestone in our path forward to a registered grass allergy product in Europe."
"Additionally," Llobet added, "this brings us closer towards marketing authorisation in the estimated USD2 billion US allergy market, a significant opportunity where our product has the potential to be the first registered subcutaneous immunotherapy for the treatment of grass allergy."
Allergy Therapeutics said around 30% of the population in Europe, and 25% in the US are allergic to grass pollen.
Shares in Allergy Therapeutics were trading 6.9% higher at 26.20 pence each on Monday.
Allergy Thera. (AGY)